(GI33) Plasma Glucagon-like Peptide-2 in Dogs with Chronic Enteropathies

Abstract:

Background: Glucagon-like peptide-2 (GLP-2) is an enteroendocrine hormone that promotes gastrointestinal mucosal growth and maintains the mucosal barrier. In humans with chronic gastrointestinal disease, mucosal pathology affects GLP-2 secretion, which normalizes with disease remission.

Hypothesis/

Objectives: Fasting and post-prandial plasma GLP-2 will be lower in dogs with chronic enteropathies (CE) compared to healthy dogs, and GLP-2 will increase with clinical disease response.

Animals: 18 client-owned dogs with uncontrolled CE, prior to directed gastrointestinal disease treatment; 17 client-owned healthy control dogs

Methods: This was a prospective study comparing plasma GLP-2 in dogs with uncontrolled CE to healthy dogs. Fasted, 1-hour, and 3-hour post-prandial blood samples were collected into chilled EDTA tubes with proteinase inhibitors. Plasma GLP-2 concentration was measured using a commercial canine ELISA. Procedures were repeated in CE dogs following 30 days of non-standardized gastrointestinal disease therapy. Mixed effects models with repeated measures were used to assess effect of study day and dog group on GLP-2 concentrations.

Results: Fasted and post-prandial GLP-2 concentrations were lower in uncontrolled CE dogs at enrollment (Fasted, 424+/-176 pg/mL; P < 0.0001) and follow-up (Fasted, 624+/-314 pg/mL; P < 0.001) compared to healthy dogs (Fasted, 1184+/-435 pg/mL). One-hour post-prandial GLP-2 concentrations were higher at recheck (720+/-247 pg/mL) compared to enrollment (439+/-169 pg/mL) in CE dogs (P = 0.02).

Conclusions: There is disrupted GLP-2 secretion in dogs with CE. Treatment for gastrointestinal disease may normalize GLP-2 secretion.